bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures from Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer
Authors: Paoletti Costanza , Muñiz Maria C. , Thomas Dafydd G. , Griffith Kent A. , Kidwell Kelley M. , Tokudome Nahomi , Brown Martha E. , Aung Kimberly , Miller M. Craig , Blossom Dorothy L. , Schott Anne F. , Henry N. Lynn , Rae James M. , Connelly Mark C. , Chianese David A. , Hayes Daniel F.
Published: April 2023

Supplementary Figures. Figure S1. Clinical trial study design. Figure S2. Examples of biomarker staining of cultured human breast cancer cell lines after spike and capture from normal human blood using the CellSearch® system. A semi-quantitative scale was established based on relative expression of each biomarker: negative (0), weak (1+), intermediate (2+), and high (3+). Footnote: *hormone depleted condition. Figure S3. Demonstration of appropriate antibody staining of cultured human breast cancer cells with known positive and negative biomarker expression after spike and capture from normal human blood using the CellSearch® System. A: ER staining for MCF-7 and Sk-Br-3. B: BCL- 2 staining for MCF-7 and Sk-Br-3. C: HER2 staining for Sk-Br-3 and MCF-7. D: Ki-67 staining for MCF-7. Figure S4. Composite "CTC-Bio-Score" for different cell lines. A: Hormone depleted MCF-7 cells (Luminal-type). B: MDA-MB-231 (Basal-like type). C: Sk-Br-3 (HER2 positive). Figure S5. Heterogeneity of ER expression within the cultured MCF-7 human breast cancer cell line. Cells were cultured in hormone depleted media for 48 hours, harvested, and spiked into 7.5 ml of normal human blood. The blood was then processed using CellSearch® and stained for DAPI, CK, CD45, and ER. Examples of strong (2+, 3+), weak (1+), and no staining (0) are displayed. Apparent staining in the bottom panel is due to high gain analysis by the automated fluorescent microscopy, as indicated by very high background. Figure S6. Coefficient of variation of CTC-enumeration by mean CTC count. Figure S7. Heterogeneity between primary tissue and CTC for patient #4. The CTC galleries displayed were selected from over 1,000 images to illustrate CTC-ER heterogeneity.
Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Authors: Patnaik Amita , Kang S. Peter , Rasco Drew , Papadopoulos Kyriakos P. , Elassaiss-Schaap Jeroen , Beeram Muralidhar , Drengler Ronald , Chen Cong , Smith Lon , Espino Guillermo , Gergich Kevin , Delgado Liliana , Daud Adil , Lindia Jill A. , Li Xiaoyun Nicole , Pierce Robert H. , Yearley Jennifer H. , Wu Dianna , Laterza Omar , Lehnert Manfred , Iannone Robert , Tolcher Anthony W.
Published: April 2023

Figure S1. Seventeen patients were tested with IFN-γ ELISPOT assay.
Supplemental Figure 4c from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 4c. QD-FISH for PTEN gene and chromosome 10 centromere demonstrate a loss of the PTEN gene in tumor cells.
Supplemental Figure 3a from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 3a. PTEN IHC assay validation and scoring. PTEN IHC was performed on a panel of FFPE breast cancer cell pellets of known PTEN status confirmed by western immunoblot. (A.) Western immunoblot analyses for MDA-MB-468, CAL-148, MDA-MB-361, MT-3, and MDA-MB-436 human breast cancer cell lines are illustrated above with PTEN IHC illustrated below.
Supplemental Figure 7-10 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplemental Figure 7-10. Figure S7: Summary of the results obtained on the TCGA data; Figure S8: Survival analysis of the patients included in the TCGA according to our classification ccrcc 1 to 4; Figure S9: Illustration of the gradient assumption defined by subtype order
Figure S5 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Authors: Zhuang Zhuonan , Ju Huai-Qiang , Aguilar Mitzi , Gocho Takashi , Li Hao , Iida Tomonori , Lee Harold , Fan Xiaoqiang , Zhou Haijun , Ling Jianhua , Li Zhongkui , Fu Jie , Wu Min , Li Min , Melisi Davide , Iwakura Yoichiro , Xu Kesen , Fleming Jason B. , Chiao Paul J.
Published: April 2023

Figure S5. A, Q-PCR assay of genetically engineered mice showed that the IL-1α -/- gene was knocked out.
Figure S4 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Authors: Zhuang Zhuonan , Ju Huai-Qiang , Aguilar Mitzi , Gocho Takashi , Li Hao , Iida Tomonori , Lee Harold , Fan Xiaoqiang , Zhou Haijun , Ling Jianhua , Li Zhongkui , Fu Jie , Wu Min , Li Min , Melisi Davide , Iwakura Yoichiro , Xu Kesen , Fleming Jason B. , Chiao Paul J.
Published: April 2023

Figure S4. A, Orthotopic xenograft tumor model shows AsPc1 PDAC tumors and an invading tumor.
Supplemental Figure S9 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Figure S9. Body weight change of mice in the efficacy experiments in the RS4;11 xenograft model shown inFig. 6C (A) and Fig. 6D (B). Data shown are mean {plus minus} SEM for 6-8 mice.
Supplemental Figure S3 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Figure S3. in vivo Study of ABT-263 or SAR405838 in the RS4;11 model in mice.
supplemental figure legend from Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
Authors: Ory Benjamin , Baud'huin Marc , Verrecchia Franck , Royer Bénédicte Brounais-Le , Quillard Thibaut , Amiaud Jérôme , Battaglia Séverine , Heymann Dominique , Redini Francoise , Lamoureux Francois
Published: April 2023

supplemental figure legend
Supplementary Figure 2 from Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Authors: Bellini Angela , Bernard Virginie , Leroy Quentin , Rio Frio Thomas , Pierron Gaelle , Combaret Valérie , Lapouble Eve , Clement Nathalie , Rubie Herve , Thebaud Estelle , Chastagner Pascal , Defachelles Anne Sophie , Bergeron Christophe , Buchbinder Nimrod , Taque Sophie , Auvrignon Anne , Valteau-Couanet Dominique , Michon Jean , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Supplementary Figure 2. Comparison of polymorphism rs3738868 allele fractions located within the intronic region between exon 25 and exon 26 (position chr2:29432625) between the first deep sequencing and validation experiment. The 263 neuroblastoma samples with a depth of coverage higher than 1000X at the polymorphism position are reported on the graph. The concordance between the two experiments is highlighted by the R-squared value
Supplemental Figure 5. from The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Authors: Zhao Shuang G. , Evans Joseph R. , Kothari Vishal , Sun Grace , Larm Ashley , Mondine Victor , Schaeffer Edward M. , Ross Ashley E. , Klein Eric A. , Den Robert B. , Dicker Adam P. , Karnes R. Jeffrey , Erho Nicholas , Nguyen Paul L. , Davicioni Elai , Feng Felix Y.
Published: April 2023

Supplemental Figure 5. Published prognostic instrument ROC AUC analysis.
Supplemental Figure 1. from The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer
Authors: Zhao Shuang G. , Evans Joseph R. , Kothari Vishal , Sun Grace , Larm Ashley , Mondine Victor , Schaeffer Edward M. , Ross Ashley E. , Klein Eric A. , Den Robert B. , Dicker Adam P. , Karnes R. Jeffrey , Erho Nicholas , Nguyen Paul L. , Davicioni Elai , Feng Felix Y.
Published: April 2023

Supplemental Figure 1. Additional prognostic outlier genes.
Supplementary Figures 1,2,3,4,5 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Authors: Vitale Candida , Falchi Lorenzo , ten Hacken Elisa , Gao Hui , Shaim Hila , Van Roosbroeck Katrien , Calin George , O'Brien Susan , Faderl Stefan , Wang Xuemei , Wierda William G. , Rezvani Katayoun , Reuben James M. , Burger Jan A. , Keating Michael J. , Ferrajoli Alessandra
Published: April 2023

Supplementary Figure 1: Ofatumumab and lenalidomide treatment schema. Supplementary Figure 2: Absolute number of responses and response rates in evaluable patients over time. Supplementary Figure 3: FACS plots showing baseline NK and T cell function in HD and CR, PR and NR patients. Supplementary Figure 4: Plasma chemokine and cytokine modulation during ofatumumab and lenalidomide treatment. Supplementary Figure 5: Changes in circulating angiogenic factors during therapy with ofatumumab and lenalidomide.
Supplemental Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Authors: Lambertz Irina , Kumps Candy , Claeys Shana , Lindner Sven , Beckers Anneleen , Janssens Els , Carter Daniel R. , Cazes Alex , Cheung Belamy B. , De Mariano Marilena , De Bondt An , De Brouwer Sara , Delattre Olivier , Gibbons Jay , Janoueix-Lerosey Isabelle , Laureys Geneviève , Liang Chris , Marchall Glenn M. , Porcu Michael , Takita Junko , Trujillo David Camacho , Van Den Wyngaert Ilse , Van Roy Nadine , Van Goethem Alan , Van Maerken Tom , Zabrocki Piotr , Cools Jan , Schulte Johannes H. , Vialard Jorge , Speleman Frank , De Preter Katleen
Published: April 2023

Supplemental data 1: Cell line information: Summary of the characteristics of cell lines used in this study including origin, tumor type, ALK and MYCN status (wt = wild type, NA = non amplified, A = amplified). Supplemental data 2: GI50 concentration of TAE-Â­â€�684 in neuroblastoma cell lines Supplemental data 3: phospho-Â­â€�ALK and total ALK expression in a panel of 10 neuroblastoma cell lines Supplemental data 4: ALK expression upon ALK inhibition using shALK Supplemental data 6: Expression of 77 ALK regulated genes in a panel of 10 neuroblastoma cell lines treated with ALK inhibitor TAE-Â­â€�684 Supplemental data 7: Expression of 77 ALK regulated genes in SK-Â­â€�N-Â­â€�AS with induced ALK Supplemental Data 8: Progression-Â­â€�free survival versus ALK signature scors Supplemental data 11: ALK signature gene analysis upon inhibition of two ALK downstream pathways Supplemental data 14:Expression of MAPK genes in CLB-Â­â€�GA after ALK inhibition Supplemental data 15: A. RET mRNA expression levels upon FOXO3 activation (+Dox) and Pi3K/AKT inhibition (+PI) in cell line SY5Y (Santo et al., 2013, GEO-Â­â€�id: GSE42762); B. pFOXO3a levels upon ALK inhibition with the LDK-Â­â€�378 compound are downregulated Supplemental data 16: Cell growth upon treatment of neuroblastoma cell lines with different concentrations of Trametinib (MAPK/MEK inhibitor) is only modestly affected Supplemental Data 17: Scheme to clarify our hypothesis
Supplemental Data 9 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Authors: Lambertz Irina , Kumps Candy , Claeys Shana , Lindner Sven , Beckers Anneleen , Janssens Els , Carter Daniel R. , Cazes Alex , Cheung Belamy B. , De Mariano Marilena , De Bondt An , De Brouwer Sara , Delattre Olivier , Gibbons Jay , Janoueix-Lerosey Isabelle , Laureys Geneviève , Liang Chris , Marchall Glenn M. , Porcu Michael , Takita Junko , Trujillo David Camacho , Van Den Wyngaert Ilse , Van Roy Nadine , Van Goethem Alan , Van Maerken Tom , Zabrocki Piotr , Cools Jan , Schulte Johannes H. , Vialard Jorge , Speleman Frank , De Preter Katleen
Published: April 2023

Supplemental data 9: Summary of Gene Set Enrichment analysis results performed on expression data upon ALK inhibition in 10 cell lines
Supplemental Table S5 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

Change in MV score (14 days - baseline) vs. RECIST response
Supplemental Table S1 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

The 57 genes of the MV score and their correlation to the microvessel density score (MVD) in the Uppsala dataset (N=180)
Supplementary Figures 1-2 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Supplementary Figure 1 - A) Vessel density in PAN02 tumors from lean and obese mice, and effect of VEGFR-1-TK-deletion on tumor vessel density and hypoxia markers in obese mice. Supplementary Figure 2 - Gene expression of M1 / M2 markers in TAMs isolated from PAN02 tumors in lean and obese mice.
Supplementary Table 5 from Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis
Authors: Crona Joakim , Backman Samuel , Maharjan Rajani , Mayrhofer Markus , Stålberg Peter , Isaksson Anders , Hellman Per , Björklund Peyman
Published: April 2023

Supplementary Table 5. Generated segmentations from SNP array data and subsequent analyses
Supplementary Figure 5 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Supplementary Figure 5 - Effects of VEGFR-1 signaling ablation on PAN02 tumor progression in body-weight matched mice.
Supplementary Figure 1 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Effect of IL-18 combined with immune checkpoint blockade on tumor growth
Supplemental Figure Legends from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Figure Legends
Supplementary figures from mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
Authors: Mo Wei , Liu Qingxin , Lin Curtis Chun-Jen , Dai Hui , Peng Yang , Liang Yulong , Peng Guang , Meric-Bernstam Funda , Mills Gordon B. , Li Kaiyi , Lin Shiaw-Yih
Published: April 2023

Supplementary figures and figure legends Supplementary Figure 1. mTOR inhibitors do not impair homologous recombination repair in non-transformed breast epithelial cells. Supplementary Figure 2. mTOR inhibitors do not affect expression of key HR-related proteins in BRCA-proficient TNBCs. Supplementary Figure 3. Microarray and Ingenuity Pathway Analysis (IPA).
Supplemental Figure 1 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Figure 1. AXL knockdown inhibits the migration of HNSCC cell lines
Supplementary Figure Legends from Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β-cell Dysfunction
Authors: Javeed Naureen , Sagar Gunisha , Dutta Shamit K. , Smyrk Thomas C. , Lau Julie S. , Bhattacharya Santanu , Truty Mark , Petersen Gloria M. , Kaufman Randal J. , Chari Suresh T. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Figure Legends
Supplementary Fig. 3 from Pancreatic Cancer–Derived Exosomes Cause Paraneoplastic β-cell Dysfunction
Authors: Javeed Naureen , Sagar Gunisha , Dutta Shamit K. , Smyrk Thomas C. , Lau Julie S. , Bhattacharya Santanu , Truty Mark , Petersen Gloria M. , Kaufman Randal J. , Chari Suresh T. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Fig. 3. Chlorpromazine and Nocodazole do not inhibit exosome internalization. INS-1 cells were treated with varying concentrations of chlorpromazine (A) or Nocodazole (C) for 30 minutes and 10 minutes, respectively. PKH67-dyed PANC-1 exosomes were then added to the cells for 5 hours to allow internalization. Scale bars represent 10 Ã‚Âµm. (B) and (D) show the quantification of internalized green fluorescence per cell for chlorpromazine (B) and Nocodazole (D) treated cells.
Supplementary Figure 4 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Figure 4. Anti-tumor effect on MB49 tumors. ADC-1013 generates a significant anti-tumor effect on CD40 negative MB49 cells in hCD40tg mice. Treatment with ADC-1013 or isotype control was performed on day 7 and 10 post tumor inoculation. Increasing doses of ADC-1013 were administred peritumorally in 100 ul PBS and the individual tumor growth curves are displayed.
Supplementary Methods, Figures 1 - 3, Tables 1 - 2 from A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
Authors: Taylor Graham S. , Jia Hui , Harrington Kevin , Lee Lip Wai , Turner James , Ladell Kristin , Price David A. , Tanday Manjit , Matthews Jen , Roberts Claudia , Edwards Ceri , McGuigan Lesley , Hartley Andrew , Wilson Steve , Hui Edwin P. , Chan Anthony T. C. , Rickinson Alan B. , Steven Neil M.
Published: April 2023

Additional detail of materials and methods used. Figure 1. Flow chart detailing dose escalation schema. Figure 2. MVA-EBNA1/LMP2 Vaccination does not alter broad subsets of immune cells. Figure 3. EBNA1 antibody response before and after MVA-EL vaccination. Table 1 MHC class I and II restricted epitope peptides in EBNA1 and LMP2 used as targets in ELIspot assays. Table 2 Summary of EBNA1- and LMP2-specific immune responses stimulated by vaccination of UK NPC patients.
Supplementary Figures S7-S9 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Figures S7-S9. S7. Use of the LumiNIR{trade mark, serif} System to surgically remove a PSMA positive xenograft in a laparoscopic setting. S8. Optimization of timing and dose. S9. Kinetic quantification of YC-27 dose response.
Supplemental Figure S4 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Figure S4: Correlation among multiplexed biomarkers
supplementary methods from Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Authors: Huang Jing , Xu Binghe , Mo Hongnan , Zhang Weilong , Chen Xuelian , Wu Dawei , Qu Dong , Wang Xingyuan , Lan Bo , Yang Beibei , Wang Pei , Zhang Hongtu , Yang Qing , Jiao Yuchen
Published: April 2023

supplementary methods
protocol from Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
Authors: Huang Jing , Xu Binghe , Mo Hongnan , Zhang Weilong , Chen Xuelian , Wu Dawei , Qu Dong , Wang Xingyuan , Lan Bo , Yang Beibei , Wang Pei , Zhang Hongtu , Yang Qing , Jiao Yuchen
Published: April 2023

protocol version 3
Supplemental Table 1 legend from Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
Authors: Piesche Matthias , Ho Vincent T. , Kim Haesook , Nakazaki Yukoh , Nehil Michael , Yaghi Nasser K. , Kolodin Dmitriy , Weiser Jeremy , Altevogt Peter , Kiefel Helena , Alyea Edwin P. , Antin Joseph H. , Cutler Corey , Koreth John , Canning Christine , Ritz Jerome , Soiffer Robert J. , Dranoff Glenn
Published: April 2023

Supplemental Table 1 legend
Supplementary Figure Legends from Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
Authors: O'Connor James P.B. , Rose Chris J. , Waterton John C. , Carano Richard A.D. , Parker Geoff J.M. , Jackson Alan
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S3 from pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma
Authors: Ruf Melanie , Mittmann Christiane , Nowicka Anna M. , Hartmann Arndt , Hermanns Thomas , Poyet Cédric , van den Broek Maries , Sulser Tullio , Moch Holger , Schraml Peter
Published: April 2023

CD3 subunits plotted against CD27 mRNA levels of the gene expression data. Results of Pearson R correlation analyses are depicted.
Supplementary Table 1 from Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Authors: Zhang Xin , Yang Xiaoyun , Zhang Yanli , Liu Xinfeng , Zheng Guixi , Yang Yongmei , Wang Lili , Du Lutao , Wang Chuanxin
Published: April 2023

Supplementary Table 1. Primer sequences and temperature conditions for real-time PCR
Figure S4 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Authors: Charych Deborah H. , Hoch Ute , Langowski John L. , Lee Steve R. , Addepalli Murali K. , Kirk Peter B. , Sheng Dawei , Liu Xiaofeng , Sims Paul W. , VanderVeen Laurie A. , Ali Cherie F. , Chang Thomas K. , Konakova Marina , Pena Rhoneil L. , Kanhere Rupesh S. , Kirksey Yolanda M. , Ji Chunmei , Wang Yujun , Huang Jicai , Sweeney Theresa D. , Kantak Seema S. , Doberstein Stephen K.
Published: April 2023

NKTR-214 produces potent immune activation in cynomolgus monkeys and is well tolerated
Supplementary Table 1 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

Primer sequences for GCLC, GCLM, NQO1, NRF2 and GAPDH analysis by real-time RT-PCR analysis.
Figure S1 from NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Authors: Charych Deborah H. , Hoch Ute , Langowski John L. , Lee Steve R. , Addepalli Murali K. , Kirk Peter B. , Sheng Dawei , Liu Xiaofeng , Sims Paul W. , VanderVeen Laurie A. , Ali Cherie F. , Chang Thomas K. , Konakova Marina , Pena Rhoneil L. , Kanhere Rupesh S. , Kirksey Yolanda M. , Ji Chunmei , Wang Yujun , Huang Jicai , Sweeney Theresa D. , Kantak Seema S. , Doberstein Stephen K.
Published: April 2023

In vitro hydrolysis of NKTR-214 under physiological conditions generating NKTR-214 released IL-2 conjugates
Supplementary Figure 3 from Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species
Authors: Garcia Jacqueline S. , Huang Min , Medeiros Bruno C. , Mitchell Beverly S.
Published: April 2023

(A) GSH to GSSG ratio, (B) reduced GSH, and (C) oxidized glutathione (GSSG) in OCI-AML3 cells (ixazomib 150nM, 22h treatment).
Summary of RNA sequencing (RNA seq) data of the Met superfamily kinases in 4 breast PDX models. from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
Authors: Bieniasz Magdalena , Radhakrishnan Parvathi , Faham Najme , De La O Jean-Paul , Welm Alana L.
Published: April 2023

Summary of RNA sequencing (RNA seq) data of the Met superfamily kinases in 4 breast PDX models.
Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Authors: Andreeff Michael , Kelly Kevin R. , Yee Karen , Assouline Sarit , Strair Roger , Popplewell Leslie , Bowen David , Martinelli Giovanni , Drummond Mark W. , Vyas Paresh , Kirschbaum Mark , Iyer Swaminathan Padmanabhan , Ruvolo Vivian , González Graciela M. Nogueras , Huang Xuelin , Chen Gong , Graves Bradford , Blotner Steven , Bridge Peter , Jukofsky Lori , Middleton Steve , Reckner Monica , Rueger Ruediger , Zhi Jianguo , Nichols Gwen , Kojima Kensuke
Published: April 2023

Supplementary Table 1. Study stratification and dosing regimen; Supplementary Table 2. p53 target genes examined in this study; Supplementary Table 3. Characteristics of evaluable patients treated at the MTD; Supplementary Table 4. Patient demographic data by cohort; Supplementary Table 5. Adverse events by grade observed in > 10% of the patients/stratum; Supplementary Table 6. Stratum pharmacokinetic parameters based on RG7112 dose regimen and formulation; Supplementary Table 7. Summary of steady state AUC for AML patients treated at the MTD; Supplementary Table 8. Clinical activity for patients with p53 mutations
Supplementary Figure S5 from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling
Authors: Liu Ronghua , Gu Jie , Jiang Pei , Zheng Yijie , Liu Xiaoming , Jiang Xuechao , Huang Enyu , Xiong Shudao , Xu Fengkai , Liu Guangwei , Ge Di , Chu Yiwei
Published: April 2023

Supplementary Figure S5. DNMT1 is the direct target of miR-126.
Supplementary Figure S4 from DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling
Authors: Liu Ronghua , Gu Jie , Jiang Pei , Zheng Yijie , Liu Xiaoming , Jiang Xuechao , Huang Enyu , Xiong Shudao , Xu Fengkai , Liu Guangwei , Ge Di , Chu Yiwei
Published: April 2023

Supplementary Figure S4. Expressions of ADAM9 in ESCC specimens, and interference efficiencies of siRNAs against ADAM9.
Supplementary Table (S5) from HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis
Authors: Abdel-Fatah Tarek M.A. , McArdle Stephanie E.B. , Agarwal Devika , Moseley Paul M. , Green Andrew R. , Ball Graham R. , Pockley A. Graham , Ellis Ian O. , Rees Robert C. , Chan Stephen Y.T.
Published: April 2023

Supplementary Table (S5). ASCO/CAP Guide lines for scoring ER, PR and HER2.
supplementary material legends from Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer
Authors: Sanz-Pamplona Rebeca , Lopez-Doriga Adriana , Paré-Brunet Laia , Lázaro Kira , Bellido Fernando , Alonso M. Henar , Aussó Susanna , Guinó Elisabet , Beltrán Sergi , Castro-Giner Francesc , Gut Marta , Sanjuan Xavier , Closa Adria , Cordero David , Morón-Duran Francisco D. , Soriano Antonio , Salazar Ramón , Valle Laura , Moreno Victor
Published: April 2023

supplementary material legends (tables and figures)
Supplementary Table S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Authors: Miltiades Paraskevi , Lamprianidou Eleftheria , Vassilakopoulos Theodoros P. , Papageorgiou Sotirios G. , Galanopoulos Athanasios G. , Kontos Christos K. , Adamopoulos Panagiotis G. , Nakou Evangelia , Vakalopoulou Sofia , Garypidou Vassilia , Papaioannou Maria , Hatjiharissi Evdoxia , Papadaki Helen A. , Spanoudakis Emmanuil , Pappa Vassiliki , Scorilas Andreas , Tsatalas Constantinos , Kotsianidis Ioannis
Published: April 2023

Multivariate analysis of prognostic factors for event-free survival in the patient cohort (n=74)
Supplementary Figure S5 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Authors: Miltiades Paraskevi , Lamprianidou Eleftheria , Vassilakopoulos Theodoros P. , Papageorgiou Sotirios G. , Galanopoulos Athanasios G. , Kontos Christos K. , Adamopoulos Panagiotis G. , Nakou Evangelia , Vakalopoulou Sofia , Garypidou Vassilia , Papaioannou Maria , Hatjiharissi Evdoxia , Papadaki Helen A. , Spanoudakis Emmanuil , Pappa Vassiliki , Scorilas Andreas , Tsatalas Constantinos , Kotsianidis Ioannis
Published: April 2023

Pretreatment signaling profiles in clonal and non-clonal CD34+ progenitors.
Supplementary Figures 1 - 9 from BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Authors: Rizos Helen , Menzies Alexander M. , Pupo Gulietta M. , Carlino Matteo S. , Fung Carina , Hyman Jessica , Haydu Lauren E. , Mijatov Branka , Becker Therese M. , Boyd Suzanah C. , Howle Julie , Saw Robyn , Thompson John F. , Kefford Richard F. , Scolyer Richard A. , Long Georgina V.
Published: April 2023

PDF file - 427KB, Figure S1 Identification of BRAFV600E splice variants in Prog tumor derived from Patient 9. Figure S2 Representative Sanger sequencing traces. Figure S3 Level of V600E BRAF allele relative to the wild type BRAF allele. Figure S4 Linear models of MEK1 and MEK2 showing functional domains. Figure S5 ATMR337C does not confer resistance to dabrafenib. Figure S6 Transcript expression analyses of additional BRAF inhibitor resistance mechanisms. Figure S7 Expression of PDGFRbeta in melanoma biopsy samples from patient 3. Figure S8 Differential expression of pAKT in two Prog tumors derived from patient 10 (Prog 1 MAPK-inhibited and Prog 2 MAPK re-activated). Figure S9 Melanoma cells expressing BRAF splice variants are resistant to dabrafenib, but retain sensitivity to trametinib.
Supplementary Figure 2 from The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Authors: Rosario Maximillian , Liu Bai , Kong Lin , Collins Lynne I. , Schneider Stephanie E. , Chen Xiaoyue , Han Kaiping , Jeng Emily K. , Rhode Peter R. , Leong Jeffrey W. , Schappe Timothy , Jewell Brea A. , Keppel Catherine R. , Shah Keval , Hess Brian , Romee Rizwan , Piwnica-Worms David R. , Cashen Amanda F. , Bartlett Nancy L. , Wong Hing C. , Fehniger Todd A.
Published: April 2023

Human NK cell engraftment and proliferation in NSG mice with ALT-803 administration.
Supplementary Table 2 from Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Authors: Hatzis Christos , Symmans W. Fraser , Zhang Ya , Gould Rebekah E. , Moulder Stacy L. , Hunt Kelly K. , Abu-Khalaf Maysa , Hofstatter Erin W. , Lannin Donald , Chagpar Anees B. , Pusztai Lajos
Published: April 2023

Power calculations for extreme scenario
Supplementary Tables from ICAM-1–Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma
Authors: Guo Weixing , Liu Shupeng , Cheng Yuqiang , Lu Lei , Shi Jie , Xu Guixia , Li Nan , Cheng Kai , Wu Mengchao , Cheng Shuqun , Liu Shanrong
Published: April 2023

Supplementary Table 1-9. Supplementary Table 1. Clinicopathologic features of 245 HCC patients with PVTT in training cohort. Supplementary Table 2. Clinicopathologic features of 372 HCC Patients in validation cohort. Supplementary Table 3. Primers and siRNA Sequences. Supplementary Table 4. Antibodies used in the study. Supplementary Table 5. lncRNAs expressed differentially both in PVTT Compared with PT and in CSQT-2 Compared with Hep3B. Supplementary Table 6. mRNAs expressed differentially both in PVTT compared with PT and in CSQT-2 compared with Hep3B. Supplementary Table 7. LncRNA-mRNA pairs from Blat analysis. Supplementary Table 8. The Relationship between expression of ICR/ICAM1 and clinicopathologic features for 372 HCC Patients. Supplementary Table 9. Univariate and Multivariate analyses of factors associated with survival and recurrence for 372 HCC patients
Supplementary Materials and Methods from ICAM-1–Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma
Authors: Guo Weixing , Liu Shupeng , Cheng Yuqiang , Lu Lei , Shi Jie , Xu Guixia , Li Nan , Cheng Kai , Wu Mengchao , Cheng Shuqun , Liu Shanrong
Published: April 2023

Methods not listed in the main manuscript including patient inclusion criteria, ChIP, ISH, IF and so on.
supplemental figure and table legend from Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
Authors: Karpathakis Anna , Dibra Harpreet , Pipinikas Chistodoulos , Feber Andrew , Morris Tiffany , Francis Joshua , Oukrif Dahmane , Mandair Dalvinder , Pericleous Marinos , Mohmaduvesh Mullan , Serra Stefano , Ogunbiyi Olagunju , Novelli Marco , Luong TuVinh , Asa Sylvia L. , Kulke Matthew , Toumpanakis Christos , Meyer Tim , Caplin Martyn , Meyerson Matthew , Beck Stephan , Thirlwell Christina
Published: April 2023

supplemental figure and table legend
Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Authors: Ortiz-Cuaran Sandra , Scheffler Matthias , Plenker Dennis , Dahmen llona , Scheel Andreas H. , Fernandez-Cuesta Lynnette , Meder Lydia , Lovly Christine M. , Persigehl Thorsten , Merkelbach-Bruse Sabine , Bos Marc , Michels Sebastian , Fischer Rieke , Albus Kerstin , König Katharina , Schildhaus Hans-Ulrich , Fassunke Jana , Ihle Michaela A. , Pasternack Helen , Heydt Carina , Becker Christian , Altmüller Janine , Ji Hongbin , Müller Christian , Florin Alexandra , Heuckmann Johannes M. , Nuernberg Peter , Ansén Sascha , Heukamp Lukas C. , Berg Johannes , Pao William , Peifer Martin , Buettner Reinhard , Wolf Jürgen , Thomas Roman K. , Sos Martin L.
Published: April 2023

Expression of KRASG12S mutant results in decreased sensitivity to AZD9291 and rociletinib in EGFR mutated cells.
Supplementary Table S3 from A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA
Authors: Ooki Akira , Maleki Zahra , Tsay Jun-Chieh J. , Goparaju Chandra , Brait Mariana , Turaga Nitesh , Nam Hae-Seong , Rom William N. , Pass Harvey I. , Sidransky David , Guerrero-Preston Rafael , Hoque Mohammad Obaidul
Published: April 2023

Supplementary Table S3.The sensitivity and specificity of the 6 genes for cancer detection in body fluids.
Supplemental Information from Kub5-HeraRPRD1B Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
Authors: Motea Edward A. , Fattah Farjana J. , Xiao Ling , Girard Luc , Rommel Amy , Morales Julio C. , Patidar Praveen , Zhou Yunyun , Porter Andrew , Xie Yang , Minna John D. , Boothman David A.
Published: April 2023

Supplementary Methods, Figures, and Tables
Supplementary Tables 1-8 from Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions
Authors: Tak Won Young , Lin Shi-Ming , Wang Yijun , Zheng Jiasheng , Vecchione Aldo , Park Soo Young , Chen Min Hua , Wong Stephen , Xu Ruocai , Peng Cheng-Yuan , Chiou Yi-You , Huang Guan-Tarn , Cai Jianqiang , Abdullah Basri Johan Jeet , Lee June Sung , Lee Jae Young , Choi Jong-Young , Gopez-Cervantes Julieta , Sherman Morris , Finn Richard S. , Omata Masao , O'Neal Michael , Makris Lukas , Borys Nicholas , Poon Ronnie , Lencioni Riccardo
Published: April 2023

Supplementary Tables 1-8 and Supplementary Figures 1-3 legends Supplementary Table 1: List of Investigators for the HEAT Study Supplementary Table 2: Summary of RFA Treatment Supplementary Table 3: Stepwise Multivariate Cox Modelling Results Supplementary Table 4: Overall Survival According to Stage Supplementary Table 5: Evaluation of Treatment Failure Supplementary Table 6: Overview of Treatment-Emergent Adverse Events Supplementary Table 7: Treatment-Emergent Adverse Events by Preferred Term Supplementary Table 8: Key Treatment-Emergent Adverse Events Among Subjects With a Solitary Tumor by 45-Minute RFA Cutpoint
supplemental figure legend from Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Bradley Conor A. , O'Reilly Paul G. , Barrett Helen L. , Cummins Robert , O'Grady Tony , Arthur Ken , Loughrey Maurice B. , Allen Wendy L. , McDade Simon S. , Waugh David J. , Hamilton Peter W. , Longley Daniel B. , Kay Elaine W. , Johnston Patrick G. , Lawler Mark , Salto-Tellez Manuel , Van Schaeybroeck Sandra
Published: April 2023

supplemental figure legend
All suupplemental figures clean from Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo
Authors: Traboulsi Wael , Sergent Frédéric , Boufettal Houssine , Brouillet Sophie , Slim Rima , Hoffmann Pascale , Benlahfid Mohammed , Zhou Qun Y. , Balboni Gianfranco , Onnis Valentina , Bolze Pierre A. , Salomon Aude , Sauthier Philippe , Mallet François , Aboussaouira Touria , Feige Jean J. , Benharouga Mohamed , Alfaidy Nadia
Published: April 2023

Supplemental Methods Figure S1: Reports clinical information's about normal pregnant women, patients with complete hydatiform moles or choriocarcinoma. Figure S2: Experimental procedure. Figure S3: Quantification of EG-VEGF PROKR1 and PROKR2 protein expression in CTL, Complete hydatiform mole (CHM) and choriocarcinoma (CC) placental section. Figure S4: EG-VEGF effect on JEG3 migration, in the absence or presence of PROKR1 or PROKR2 antagonists. Figure S5: JEG3-luc injected mice exhibited arrested gestation and disorganized vascularization. Figure S6: Antibody microarray analysis. Figure S7: Characterization of the angiogenic status of sera and placentas collected from CTL, CHM and CC patients. Figure S8: Antibody angiogenic microarray analysis of sera collected from CTL, CHM and CC patients.
Vorinostat combined with osimertinib prompts transcription of active BIM isoform in cells which are homozygous for the BIM deletion polymorphism. from Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Authors: Tanimoto Azusa , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Yamada Tadaaki , Roca Xavier , Ong S. Tiong , Yano Seiji
Published: April 2023

A, Comparison of ratio of BIM exon 3 to exon 4 transcripts in PC-9, PC-3, and PC-9BIMi2-/- cells. *, P < 0.05 PC-9 versus PC-3 or PC-3 versus PC-9BIMi2-/-. B, Alteration of transcripts containing BIM exon 2A, exon 3, and exon 4 in PC-9BIMi2-/- cells after treatment with gefitinib (1 µmol/L), osimertinib (1 µmol/L), and/or vorinostat (3 µmol/L) for 12 hours.
Table S4 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

A full list of mutations identified in SCC and MCT samples
HDAC3 inhibitory activity is important for the transcription of BIM exon 4-containing isoforms. from Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Authors: Tanimoto Azusa , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Yamada Tadaaki , Roca Xavier , Ong S. Tiong , Yano Seiji
Published: April 2023

Relative mRNA expression of BIM exon 2A, exon 3, and exon 4, by RT-PCR and ratio of exon 3 to exon 4 transcripts in PC-9BIMi2-/- cells treated with droxinostat (3 µmol/L) (A) or RGFP966 (5 µmol/L) (B) for 12 hours. *, P < 0.05 versus control.
Figure S3 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Phasing data for two tumors with bi-allelic TP53 mutations
Supplementary Figure 1 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Authors: Lamberts Laetitia E. , Koch Maximillian , de Jong Johannes S. , Adams Arthur L.L. , Glatz Jürgen , Kranendonk Mariëtte E.G. , Terwisscha van Scheltinga Anton G.T. , Jansen Liesbeth , de Vries Jakob , Lub-de Hooge Marjolijn N. , Schröder Carolien P. , Jorritsma-Smit Annelies , Linssen Matthijs D. , de Boer Esther , van der Vegt Bert , Nagengast Wouter B. , Elias Sjoerd G. , Oliveira Sabrina , Witkamp Arjen J. , Mali Willem P.Th.M. , Van der Wall Elsken , van Diest Paul J. , de Vries Elisabeth G.E. , Ntziachristos Vasilis , van Dam Gooitzen M.
Published: April 2023

Near-Infrared Optical Imaging of Positive Tumor Margin.
Supplementary Figure S1 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Authors: Becht Etienne , de Reyniès Aurélien , Giraldo Nicolas A. , Pilati Camilla , Buttard Bénédicte , Lacroix Laetitia , Selves Janick , Sautès-Fridman Catherine , Laurent-Puig Pierre , Fridman Wolf Herman
Published: April 2023

Supplementary Figure 1 : Design and use of the Microenvironment Cell Populations (MCP)-counter algorithm a) Heatmap representation of the expression of selected transcriptomic markers underlying MCP-counter scores in transcriptomic profiles corresponding to microenvironment cell populations. These scores have been quantitatively validated for their ability to predict the abundance of the corresponding cell population from the gene expression profile of a cellularly heterogeneous sample. b) MCP-counter is implemented as an R package, which takes as input transcriptomic profiles of cellularly heterogeneous tissues, such as tumors. It first maps the previously-identified transcriptomic markers to the assayed gene-expression features (as illustrated here for the 'discovery' CIT CRC cohort, and summarize them to output a score per cell population per sample. These scores can then be used to compare samples against each-others and to determine whether a group of samples is more highly infiltrated by a given cell type than another group of samples.
Table S7 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Sun Jie , Meng Hua , Yao Lu , Lv Meng , Bai Jian , Zhang Jianguang , Wang Lientu , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Multivariate Analyses of Disease-free Survival and Disease-specific Survival
Supplemental data figure legends from Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Delpuech Oona , Hancox Urs , Trinidad Antonio G. , Michopoulos Filippos , Lenaghan Carol , McEwen Robert , Bradford James , Polanski Radek , Ellston Rebecca , Avivar-Valderas Alvaro , Pilling James , Staniszewska Anna , Cumberbatch Marie , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supplemental data figure legends
Table S1 from Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Authors: Hijioka Susumu , Hosoda Waki , Matsuo Keitaro , Ueno Makoto , Furukawa Masayuki , Yoshitomi Hideyuki , Kobayashi Noritoshi , Ikeda Masafumi , Ito Tetsuhide , Nakamori Shoji , Ishii Hiroshi , Kodama Yuzo , Morizane Chigusa , Okusaka Takuji , Yanagimoto Hiroaki , Notohara Kenji , Taguchi Hiroki , Kitano Masayuki , Yane Kei , Maguchi Hiroyuki , Tsuchiya Yoshiaki , Komoto Izumi , Tanaka Hiroki , Tsuji Akihito , Hashigo Syunpei , Kawaguchi Yoshiaki , Mine Tetsuya , Kanno Atsushi , Murohisa Go , Miyabe Katsuyuki , Takagi Tadayuki , Matayoshi Nobutaka , Yoshida Tsukasa , Hara Kazuo , Imamura Masayuki , Furuse Junji , Yatabe Yasushi , Mizuno Nobumasa
Published: April 2023

Supplementary Table S1. Breakdown of chemotherapy response regimens for PanNEN-G3 (55 cases)
Figure S2 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

Enhanced apoptosis of Ba/F3-ITD and 32D/ITD cells treated with FLT3 inhibitors at serial concentrations in the presence of AZD1208.